Heartbeat’s Post

Sharing a nice summary of conversations I had after the 2023 #clinicaltrials in #oncology #europe (CTOEU2023) meeting in Munich! On the topic of #patientcentricity and #patientengagement in clinical trials. We need to work collectively through the challenges and seize the opportunities to transform the conduct of clinical trials to be more #inclusive of more patients and prioritise their needs for participation #patientsfirst

🔍 Q&A Insight: Navigating Oncology Trials' Complex Terrain 🔬 🎙️ Pauline Frank, a beacon in the field of clinical research, recently shared her reflections from the 2023 CTO Europe conference. Her session, rooted in her experience as the former director of patient engagement at Novartis, shed light on the intricate complexities of conducting oncology trials. 🚀 Despite advancements, these trials face significant hurdles, notably in patient awareness and diversity. Pauline's dialogue with Pharmaceutical Technology delves into these challenges and explores the potential of digital technologies in revolutionizing these complex trials. 🔑 Key Challenges for Patients: Lack of public awareness about clinical trials Misconceptions and communication barriers Geographic and language limitations affecting patient participation 🤔 Improving Patient Engagement: Enhancing health literacy Developing effective communication materials Considering the patient's perspective in trial design 🌍 The Digital Dilemma: Need for a tailored approach based on patient demographics Importance of human interaction alongside digital tools 📣 Social Media & Health Literacy: Leveraging social media for awareness and recruitment Tailoring messages to specific patient groups 🌈 Fostering Diversity in Trials: Engaging physicians from diverse backgrounds Providing materials in native languages and understanding cultural nuances 👏 A big thanks to Pauline Frank for her invaluable contributions and insights! #OncologyTrials #PatientEngagement #ClinicalResearch #DigitalHealth #DiversityInHealthcare #CTOEurope2023 #Novartis

🔬 Oncology is one of the biggest challenges for modern medicine. The variety, complexity and severity of the disease keep doctors and researchers constantly looking for ways to improve treatment in different ways. 📑 A review by Cureus Journal of Medical Science looks at how digital health can help in this multifaceted solution for oncology patients. 💡 It discusses potential for early detection, personalized treatment, enhanced care coordination, patient empowerment, accelerated research, and cost efficiency. It also acknowledges the challenges, including ethical considerations regarding privacy, equitable access, and responsible data usage. "The landscape of digital health in oncology is marked by incredible promise and transformative potential," concludes the article. Through our collaborative efforts and innovative products, we aim to make significant strides in these areas, My Medic Eye is committed to tackling the challenges of accessibility, equality of care, patient engagement and families' involvement in the situation and treatment of their loved ones. Our free app empowers users by facilitating efficient management of medical records and active participation in their treatment journeys. Building upon this success, our upcoming tool will streamline information exchange among caregiver services, clinics, and medical centers. This innovation not only enhances patient care but also supports medical teams and ensures smooth administrative processes. Are you ready to join us on this transformative journey? Contact us today to learn more 🚀 Link to the full review: https://lnkd.in/dXSsnfak #DigitalHealth #HealthcareInnovation #PatientCare #MedicalTechnology

Many of our clients realize the value of embedding the patient voice early in the drug development process, starting in clinical trials. Sprout's Kelsie Brewer is the newest member of our Clinical Outcomes Assessment (COA) team, specialists who advise biotech and HEOR clients on building clinical endpoints that resonate with patients and are on track for regulatory success. Kelsie brings expertise in patient-centered qualitative research across rare disease, oncology, neurology, and rheumatology. Read more about Kelsie and the work she is most excited about. #PatientVoice #ClinicalOutcomes #HEOR

Excited to join the IQVIA team at DPE! Tuesday 9:15 am Healthcare 2028: The Strategic Importance of Brand Marketing on the Future of Personalized Medicine. The healthcare industry is on the brink of profound transformation, affecting how brands go to market - from clinical to commercialization and beyond. In the next five years, approximately 250 to 270 novel therapies are expected to debut, with a significant portion in specialized domains like Oncology, Immunology, and Obesity. These advancements aim to enhance life quality and survival rates for patients across various diseases. As medicine evolves towards specialization and personalization, it's crucial for brand marketers to adapt and lead. Join IQVIA Digital and the IQVIA Institute to explore: - How innovation and technology are driving healthcare forward. - The pivotal role of digital marketing in navigating future challenges. - Strategies to captivate audiences with personalized approaches. - Methodologies to assess engagement effectiveness. Featuring speakers Murray Aitken, SVP, Executive Director, IQVIA Institute for Human Data Science, and Andrew Burkus, Senior Principal, IQVIA. #Healthcare #BrandMarketing #PersonalizedMedicine #IQVIA #DigitalMarketing #HealthcareInnovation #FutureOfMedicine

🔬 Did you know that behind every medical breakthrough are #ClinicalTrials and the brave people who participate in them? With their commitment, each volunteer not only gets closer to a possible new solution for their own #health, but also helps #Science save or improve millions of lives in the future. 💊 These trials are the last critical step in the long process of new drug research and development. From the selection of new molecules to the post-marketing monitoring of a drug, they represent the cornerstone that ensures that treatments are not only effective, but also safe for everyone. 🌍 That's why today, on #InternationalClinicalTrialDay, we want to highlight their great contribution to #MedicalResearch and to the transformation of thousands of lives. From Bristol Myers Squibb we are proud to be part of this milestone thanks to the development of multiple clinical trials involving an increasing number of patients in #Oncology, #Hematology, #Cardiology, #Immunosciences and other areas. 🧪 🤝🏼 Our sole objective is to continue transforming patients' lives through our innovative #Science, and to this end we are grateful for the fundamental role that institutions, researchers, healthcare professionals and, especially, patients play in clinical trials. Thank you all! ❤️ Discover the importance of clinical trials and the positive impact patients have on the advancement of medicine with this video. Press play! ▶️ 🔗 More information at https://lnkd.in/dB-efXjm #InternationalClinicalTrialDay #MedicalResearch #ClinicalTrials #GlobalHealth #ValentPatients #BMSIberia #BMSPortugal #BMSCommunity #BMSTransformingLives #WorkingTogetherforPatients #BMSTransformingPatientsLives 

🌟 New Diagnostic Tool for Demyelinating Neuropathies from Mayo Clinic Laboratories 🌟 At Mayo Clinic Laboratories, we continually strive to deliver expert-backed testing that helps physicians better diagnose and treat complex conditions. Our latest offering, the Peripheral Nervous System Demyelinating Neuropathy, Autoimmune Evaluation (DMNES) test, is designed to provide more accurate diagnosis for conditions like: - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Guillain-Barré Syndrome (GBS) - Autoimmune Nodopathy, and more 🔑 Key Advantages: - Helps differentiate between disease etiologies in patients with demyelinating neuropathy - Detects 7 specific antibodies aligned with electrophysiological findings - Results guide prognosis, treatment decisions, and aid in searching for underlying hematological cancers - Our report includes detailed interpretive comments for physicians Listen to the Experts: In our latest "Answers From the Lab" podcast, Dr. John Mills and Dr. Divyanshu Dubey explain how this new test can help identify the specific cause of demyelinating neuropathies and guide personalized treatment for rapidly progressing autoimmune conditions. 🔗 Tune in to learn more: Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S. - Insights (mayocliniclabs.com). Feel free to connect if you're interested in exploring this groundbreaking diagnostic tool or learning more about how Mayo Clinic Laboratories is advancing patient care! #Neurology #DemyelinatingNeuropathy #CIDP #GBS #AutoimmuneNeurology #healthcare #MayoClinicLaboratories #ClinicalDiagnostics

🚨 Join Us at AVBCC Conference, October 16-19! 🚨 Excited to announce that we will be participating in a panel discussion at the AVBCC Conference, focusing on the future of radiation oncology and what it takes to ensure access, improve quality, and stabilize payments under a value driven model. 💡 Our expert panel brings together leaders from industry, payers, health policy, and physicians to tackle some of the biggest challenges and trends in the field. We'll cover key topics such as: 1️⃣ Standardization vs. Personalization in clinical pathways—finding the balance with AI and precision medicine. 2️⃣ Multidisciplinary Integration—how clinical pathways can ensure seamless coordination across treatment modalities. 3️⃣ Value-Based Care—designing pathways that align with value-based models, reduce costs, and improve outcomes. 4️⃣ Access to Advanced Technologies—ensuring equitable access to cutting-edge treatments, especially for underserved populations. 5️⃣ Data-Driven Pathways—using real-world evidence and analytics to continuously improve patient outcomes. 6️⃣ Navigating Regulatory and Legal Challenges—addressing prior authorization, Medicare/Medicaid reforms, and compliance. 7️⃣ Telemedicine and Digital Health—incorporating remote care and digital tools into clinical pathways. 8️⃣ AI and Machine Learning—how AI-driven tools will shape the future of clinical pathway development. 9️⃣ Global Perspectives—learning from international approaches to radiation therapy access and pathway development. 🔟 Clinical Trials Integration—accelerating innovation through adaptive trials and real-time data. This is a can't-miss discussion for anyone invested in the future of radiation oncology! Be sure to join us for insights that will drive the path forward. 🌟 Lalan Wilfong, M.D. CancerX Moonshot OncoDaily OncoHealth Carrum Health Cardinal Health McKesson The US Oncology Network Florida Blue Premera Blue Cross Takeda Pfizer Seema Verma American Hospital Association American Medical Association Burt Zweigenhaft National Rural Health Association Douglas Flora, MD, LSSBB, FACCC #AVBCC #RadiationOncology #ClinicalPathways #ValueBasedCare #HealthPolicy #OncologyInnovation #HealthcareLeadership #AIinHealthcare

Campaign Spotlight: Grey Matters – A Brain Tumor Awareness Campaign In June, we launched the "Grey Matters" campaign, focused on raising awareness about brain tumors. This initiative was deeply meaningful, aiming to educate and engage people on a critical health issue that often goes unnoticed. After the campaign, we conducted a post-marketing assessment to evaluate its reach and impact. I was thrilled to see that our multidimensional approach, including digital media, patient stories, and collaborations with healthcare professionals, resulted in an exceptionally strong reach. Our estimates revealed that our message resonated with a broad audience, demonstrating the power of a well-rounded strategy. Why Post-Marketing Assessment Matters: Campaigns like "Grey Matters" are only as effective as their ability to reach and influence the target audience. Post-marketing assessment is crucial as it allows us to: 1. Measure Impact: Understand the extent of our campaign’s reach and effectiveness. 2. Gather Insights: Learn what worked and what didn’t, enabling us to refine our strategies for future campaigns. 3. Prove Value: Demonstrate the campaign’s value to stakeholders through tangible results. 4. Continuous Improvement: Drive future initiatives with data-driven decisions, ensuring we keep making healthcare better. Through these assessments, we ensure that our efforts are not just a one-time event but a continuous process of learning and improving, ultimately making a bigger impact on patient lives. #HealthcareMarketing #BrainTumorAwareness #PostMarketing #PatientEngagement #HealthCampaigns #ContinuousImprovement #HealthcareInnovation ---------------------‐-------------------------------------------- Disclaimer: The estimates shared here are based on my personal analysis. They do not reflect official statistics from Stryker, and I am not speaking on behalf of the organization. The insights shared are my own subjective observations and interpretations.

We're thrilled to share the CINDERELLA Clinical Trial presentation video ⭐ Disclaimer: This video, created for educational purposes, offers a glimpse into our innovative trial. While it may not fully represent every participant's experience, it captures the essence of our research. 🎥 Watch the video: https://lnkd.in/d_Yzbzdk The CINDERELLA Clinical Trial evaluates an AI-based tool's impact on clinical decisions for breast cancer surgery and is divided into two study arms: - Control Arm: receives standard medical care and advice. - Intervention Arm: utilises the CINDERELLA APP alongside standard care. Both arms are crucial in understanding the APP's potential to enhance breast cancer care. We encourage everyone to view and share our video. Your support can positively impact countless lives and shape the future of digital healthcare. This study is ongoing at six clinical centres: A. Champalimaud Foundation - Lisbon, Portugal B. University Hospital Heidelberg (UKHD) - Heidelberg, Germany C. Ospedale San Raffaele - Milano, Italy D. Sheba Medical Center, Tel Hashomer - Ramat Gan, Israel E. Gdański Uniwersytet Medyczny (Medical University of Gdańsk) - Gdańsk, Poland F. Copernicus Mamma Centrum, Wojewodzkie Centrum Onkologii, Copernicus Podmiot Leczniczy - Gdańsk, Poland Maria João Cardoso, Oreste Davide Gentilini, Orit Kaidar-Person, Maciej Bobowicz, Paweł Kabata MD, PhD, Prof. Dr. Timo Schinköthe, Oriana Ciani, Jaime Cardoso, Marilia Antunes, Giovani Silva, Henrique Martins, #JoergHeil SDA Bocconi CANKADO INESC TEC Centro de Estatística e Aplicações da Universidade de Lisboa #CINDERELLAProject #AIInHealthcare #DigitalHealthInnovation #horizoneu #BreastCancerAwareness #MakingADifference #BreastCancer